Cell line · CVCL_0505
Papers42
1 to 20 of 42
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Auranofin Potentiates Cisplatin Response in the Setting of Context-Dependent NOTCH-Associated Signaling States in Endometrial Cancer. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| p190A/ARHGAP35 and p190B/ARHGAP5 proteins in endometrial cancer: a novel cancer-relevant paralog interplay. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HRAS promotes mutant NRAS-driven transformation with codon and allele specificity. | Sci Signal | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Steroid-Metabolizing Enzymes with 15β-Substituted Estrone Analogues: Dual Discovery of AKR1C2/17β-HSD1 Inhibitors and a Fluorescent 17β-HSD1 Ligand. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| NSD1-Mediated PPARγ Methylation Enhances PTEN Activity to Suppress Glycolysis and Tumor Progression in Endometrial Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Impact of JAK1 Pathogenic Variants and MHC-I Expression on Response to Immune Checkpoint Inhibition in Endometrial Cancer. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Wild-type RAS signaling is an essential therapeutic target in RAS-mutated cancers. | Sci Signal | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Pathway metabolite ratios reveal distinctive glutamine metabolism in a subset of proliferating cells. | Mol Syst Biol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Functional Profiling of p53 and RB Cell Cycle Regulatory Proficiency Suggests Mechanism-Driven Molecular Stratification in Endometrial Carcinoma. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Multi-omic analyses identified SFRP4 as a novel biomarker in abnormal uterine bleeding with ovulatory dysfunction. | Heliyon | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Pyroptosis-associated genes and tumor immune response in endometrial cancer. | Discov Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Pre-receptor regulation of 11-oxyandrogens differs between normal and cancerous endometrium and across endometrial cancer grades and molecular subtypes. | Front Endocrinol (Lausanne) | 2024 | Its Methods give the RRID and name the line | PubMed | |
| PELP1 inhibition by SMIP34 reduces endometrial cancer progression via attenuation of ribosomal biogenesis. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of a lower potency target drives the anticancer activity of a clinical p38 inhibitor. | Cell Chem Biol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Physiological Concentrations of Cimicifuga racemosa Extract Do Not Affect Expression of Genes Involved in Estrogen Biosynthesis and Action in Endometrial and Ovarian Cell Lines. | Biomolecules | 2022 | Its Methods give the RRID and name the line | PubMed | |
| In the Model Cell Lines of Moderately and Poorly Differentiated Endometrial Carcinoma, Estrogens Can Be Formed via the Sulfatase Pathway. | Front Mol Biosci | 2021 | Its Methods give the RRID and name the line | PubMed | |
| MET Mutation Is a Potential Therapeutic Target for Advanced Endometrial Cancer. | Cancers (Basel) | 2021 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0505/papers